8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

DEF 14A - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

S-8 - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

10-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

SCHEDULE 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SCHEDULE 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

Maxim Group initiated coverage of Kiora Pharmaceuticals with a rating of Buy and set a new price target of $2.50

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

Amendment eliminates $4.75M in near-term milestones Kiora would have owed to SentrxSentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary useKiora will receive a royalty on net sales of products covered by licensed patentsEncinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora") and Sentrx Animal Care ("Sentrx") announced today they have amended their existing licensing agreement for patents and technology related to Kiora's KIO-201 product candidate. The amended agreement between the companies eliminates up to $4.75M in near-term financial payments by Kiora to Sentrx that w

Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA).CEO Commentary"This has been a pivotal quarter for our business resulting in several recently reported clinical development milestones," said Brian M. Strem, Ph.D., president and CEO of Kiora. "Last month we reported preliminary results from our open-label study of KIO-301, our flagship asset, demonst

Encinitas, California--(Newsfile Corp. - May 1, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled "Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal 'Photoswitch' Molecule (KIO-301): Functional MRI Protocol and Preliminary In-Human Observations" will be presented by Christen Barras, MBBS, Ph.D., Neuroradiologist at Jones Radiology, Associate Professor of Radiology at the University of Adelaide, in Adelaide, Australia and a co-investigator in the study.Patients with Retinitis Pigmentosa (RP)

Encinitas, California--(Newsfile Corp. - April 27, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis pigmentosa. KIO-301 is a light-sensing small molecule designed to reactivate visual function of the eye in response to light. The results were presented today at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. To view a full multimedia version of this announcement, including downloadable images, videos, graphics, presentation slide

In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis.Encinitas, California--(Newsfile Corp. - April 26, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) presented results of a Phase 2 clinical trial for KIO-201 treating patients with Persistent Corneal Epithelial Defects (PCEDs) at the Association for Research in Vision and Ophthalmology (ARVO) Meeting in New Orleans.KIO-201 is a chemically modified and cross-linked form of hyaluronic acid designed to accelerate corneal wound healing. The results of the clinical trial demonstrate that KIO-201 is a promising treatment for PCEDs, which are challenging to treat and can lea

Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific Advisory Board, his expertise and insights will contribute to the company's development of new treatments and therapies for patients suffering from eye diseases, including retinitis pigmentosa, a rare inherited degenerative eye disease in which Kiora is enrolling a clinical tri

Encinitas, California--(Newsfile Corp. - April 17, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) enrolled the first patient in its Phase 2 trial of KIO-101 in the treatment of the Ocular Presentations of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This clinical trial is a phase 2, multi-center, controlled, randomized, double-masked study targeting enrollment of up to 120 patients. Participants will receive one of two doses of KIO-101 (0.15% and 0.30%) or a placebo. Efficacy endpoints will evaluate established ocular signs and symptoms, including but not limited to corneal staining and changes in the Schirmer's test score at 12 weeks. The study will also evaluate several safety

Encinitas, California--(Newsfile Corp. - March 30, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") announced its late-breaking abstract detailing functional Magnetic Resonance Imaging (fMRI) results from the ABACUS Phase 1b study of KIO-301 in patients with retinitis pigmentosa was accepted for presentation on May 1, 2023, at The American Society of Neuroradiology 2023 (ASNR23) Annual Meeting.Christen Barras, MBBS, Ph.D., Neuroradiologist at Jones Radiology, Associate Professor of Radiology at the University of Adelaide, in Adelaide, Australia, and an investigator in the ABACUS study, will present fMRI results for initial patients treated with KIO-301, a novel l

Encinitas, California--(Newsfile Corp. - March 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results for the year ended December 31, 2022.CEO Commentary: "In 2022, we advanced our pipeline of three differentiated assets across rare, orphan and underserved eye disease indications," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "Enrollment is ongoing in our Phase 1b study of KIO-301 in patients with Retinitis Pigmentosa (RP); we initiated a Phase 2 study of KIO-101 in patients whose autoimmune disease manifests on the ocular surface; and we recently completed a Phase 2

Encinitas, California--(Newsfile Corp. - March 10, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") today announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, La., April 23-27, 2023. Further results from each of these three studies will be reported at the conference.A presentation will report interim results on safety, tolerability and efficacy from the ABACUS study, the ongoing, first-in-human clinical trial of KIO-301, a small-molecule photoswitch, intended to restore sight in patients with the orphan disease, retinitis pigmentosa. A second presentat

Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ:KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific Advisory Board, his expertise and insights will contribute to the company's development of new treatments and therapies for patients suffering from eye diseases, including retinitis pigmentosa, a rare inherited degenerative eye disease in which Kiora is enrolling a clinical tri

Salt Lake City, Utah--(Newsfile Corp. - September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning. "Melissa brings to our company more than 15 years of financial and operational experience in both clinical and commercial-stage biotech and life science companies," said Brian M. Strem, Ph.D., President and CEO of Kiora. "This experience will be invaluable to our goals of advancing our development pipeline and

Salt Lake City, Utah--(Newsfile Corp. - February 1, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") announced today the appointment of Erin Parsons as a new independent Director of its Board of Directors (the "Board"). Separately, the Executive Chairman, Stephen From, has informed Kiora of his voluntary resignation from the Board. These changes are effective immediately. "I am pleased to welcome Erin Parsons to our Board of Directors," said Brian M. Strem, Ph.D, President and CEO of Kiora. "Erin brings extensive commercial and strategic expertise in eyecare, a critical and complementary perspective as we continue to dedicate efforts to develop therapeutics for e

Salt Lake City, Utah--(Newsfile Corp. - December 15, 2021) - Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) ("Kiora" or the "Company") announced the appointment of David Hollander, MD, MBA, to its Board of Directors. Dr. Hollander, who currently serves as the Chief Research and Development Officer of Aerie Pharmaceuticals, Inc. ("Aerie"), brings extensive ophthalmic industry expertise and insight to the Company's board. "Kiora has a compelling development pipeline, including KIO-301, a clinical-ready small molecule with the potential to restore vision in patients with Retinitis Pigmentosa, a rare, genetic form of blindness," said Dr. Hollander. "Further, the recently reported topline KIO-101 dat

SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

SC 13G - KIORA PHARMACEUTICALS INC (0001372514) (Subject)